Journals
View articles of the highest standard and extending to all aspects of human health
Specialties
View collections of articles, reviews, seminars and comments from across our journals
Clinic
View selected content around 136 diseases according to clinical practice needs
Global Health
View selected content to advance health in all regions of the world
HIV-related haematological malignancies
Published: August 10, 2020
Since the earliest days of the HIV epidemic, haematological malignancies have been a defining feature of illness caused by the virus; individuals with HIV are living longer and contending with the challenges of treating cancer while on ART, now, work on haematological cancers is providing insights into how a cure for HIV might be achieved.
Endocrine-disrupting chemicals
The Lancet Diabetes & Endocrinology
Published: July 22, 2020
Endocrine-disrupting chemicals (EDCs) represent not just a threat to public health or indeed to global health, but to planetary health. Pervasive in our environment—in foods, packaging materials, cosmetics, drinking water, and consumer products—EDCs have been linked to a myriad of non-communicable diseases such as obesity, type 2 diabetes, thyroid disorders, neurodevelopmental disease, hormone-dependent cancers, and reproductive disorders.
Institutionalisation and deinstitutionalisation of children
Published: June 23, 2020
This Lancet Group Commission advocates global reform of the care of separated children through the progressive replacement of institutional provision with safe and nurturing family-based care. It provides essential information on both the global scale of institutionalisation and its physical, social, and mental health consequences. It presents a pragmatic roadmap for carefully managed change.
Sustainable care for children with cancer
The Lancet Oncology
Published: March 30, 2020
Cancer kills more than 100,000 children each year, and yet 80% of paediatric cancers are curable with currently available interventions. Notably, the majority of these deaths occur in low‐income and middle-income countries where children have poor access to health services. It is crucial that as countries transition to universal health care, childhood cancers are recognised as a priority for inclusion in benefits packages. Yet no reliable data are available in low-income and middle-income countries on the current and future burden of childhood cancer; on cost of effective interventions; on current coverage levels for diagnostic, treatment, and care services; or on the cost, feasibility, or health and economic benefits of scaling-up effective coverage. There is an imperative for a comprehensive study to estimate the number of new cases, survival with and without treatment, the number of deaths without additional investments to scale up health services and treatment for children with cancer, and to develop an investment framework to establish an evidence-based case for investing in effective interventions to address childhood cancer. In a new Commission from The Lancet Oncology, Rifat Atun, Carlos Rodriguez-Galindo, and colleagues provide a comprehensive analysis to develop an investment case for funding management and control of childhood cancer.